ROYAL BANK OF CANADA - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 63 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$134,000
+15.5%
8,059
+91.1%
0.00%
Q2 2023$116,000
+90.2%
4,217
+60.1%
0.00%
Q1 2023$61,000
+1.7%
2,634
-52.5%
0.00%
Q4 2022$60,000
+757.1%
5,543
+583.5%
0.00%
Q3 2022$7,000
+75.0%
811
+59.0%
0.00%
Q2 2022$4,000
-94.4%
510
-83.0%
0.00%
Q1 2022$71,000
-79.4%
3,000
-70.2%
0.00%
Q4 2021$345,000
+305.9%
10,067
+110.4%
0.00%
Q3 2021$85,000
-43.0%
4,785
+43.7%
0.00%
Q2 2021$149,000
+73.3%
3,330
+0.2%
0.00%
Q1 2021$86,000
+258.3%
3,324
+179.3%
0.00%
Q4 2020$24,000
+140.0%
1,190
+138.0%
0.00%
Q3 2020$10,000
+11.1%
5000.0%0.00%
Q2 2020$9,000500
+861.5%
0.00%
Q1 2020$0
-100.0%
52
-95.3%
0.00%
Q4 2019$8,000
+166.7%
1,102
+120.4%
0.00%
Q4 2018$3,000
-40.0%
500
-1.4%
0.00%
Q3 2018$5,000
+66.7%
507
+26.8%
0.00%
Q2 2018$3,000
+50.0%
400
+122.2%
0.00%
Q1 2018$2,000
+100.0%
180
+153.5%
0.00%
Q4 2017$1,000
-92.3%
71
-90.6%
0.00%
Q3 2017$13,000
+1200.0%
758
+1357.7%
0.00%
Q2 2017$1,000
-66.7%
52
-78.6%
0.00%
Q1 2017$3,000
-62.5%
243
-31.9%
0.00%
Q4 2016$8,000
+100.0%
357
+78.5%
0.00%
Q3 2016$4,0002000.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q3 2018
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$67,646,43421.00%
COWEN AND COMPANY, LLC 1,657,551$45,781,5583.80%
Kynam Capital Management, LP 975,298$26,937,7313.70%
BVF INC/IL 3,775,900$104,290,3582.91%
RTW INVESTMENTS, LP 5,415,514$149,576,4972.85%
Cormorant Asset Management, LP 1,500,000$41,430,0002.32%
Ghost Tree Capital, LLC 225,000$6,214,5002.05%
683 Capital Management, LLC 814,000$22,482,6801.62%
Perceptive Advisors 1,469,761$40,594,7991.18%
Artia Global Partners LP 112,340$3,102,8311.07%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders